# JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

> **NCT06689917** · NA · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 20 (estimated)

## Conditions studied

- B-ALL
- B-NHL

## Interventions

- **DRUG:** JY231 Injection

## Key facts

- **NCT ID:** NCT06689917
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06689917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06689917, "JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06689917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*